BriaCell and BriaPro to Showcase Immunotherapy Research at SITC 2026

  • BriaCell and BriaPro will present four posters at the SITC 2026 Annual Meeting, November 4-8, 2026.
  • Topics include BriaCell’s Bria-OTS+™ immunotherapy and BriaPro’s tumor-targeted checkpoint inhibitors.
  • Posters detail preclinical research on CD80 variants and soluble CD80 dimer (BP-80).
  • Presentations scheduled for November 6 and 7, 2026, in Phoenix, AZ.

BriaCell and BriaPro’s participation in SITC 2026 underscores the growing emphasis on immunotherapy in cancer treatment. The presentations highlight the companies’ focus on novel approaches, including personalized off-the-shelf therapies and engineered checkpoint inhibitors, which could position them as key players in the evolving oncology landscape. The event provides a platform to showcase preclinical advancements, potentially attracting investor and partner interest.

Clinical Validation
How preclinical data translates into clinical success for BriaCell’s Bria-OTS+™ and BriaPro’s checkpoint inhibitors.
Regulatory Pathway
The pace at which BriaCell advances its immunotherapy candidates through regulatory approvals.
Competitive Positioning
Whether BriaCell and BriaPro can differentiate their immunotherapy approaches in a crowded market.